Literature DB >> 16321855

Comparative genomic hybridization analysis of Japanese B-cell chronic lymphocytic leukemia: correlation with clinical course.

Kunihiro Tsukasaki1, Dirk Lohr, Kazuyuki Sugahara, Shimeru Kamihira, Masao Tomonaga, Claus R Bartram, Anna Jauch.   

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia in Westerners. By contrast, B-CLL is rare in Asians, including Japanese. We applied comparative genomic hybridization (CGH) to screen 26 newly diagnosed Japanese B-CLL patients for genomic aberrations. Chromosomal imbalances were detected in 12 of the 26 cases (46%). The most frequent changes observed were gains of chromosomes 3q in five cases (19%) and 17q in three cases (12%). Other recurrent imbalances included gains of chromosomes 8q, 18q and losses of chromosomes 13q and 17p. Samples obtained at different sites disclosed identical CGH findings in all of the three cases examined. Genomic imbalances as detected by CGH were associated with disease progression and shorter survival. Two patients, with chromosomal imbalances, including gains of both 3q and 18q, developed large cell transformation of the disease within 4 years. In conclusion, CGH abnormality was associated with poor prognosis in Japanese B-CLL, and features of Japanese B-CLL, compared to chromosomal abnormalities of Western B-CLL in the literature, include a lower incidence of any abnormality in particular regarding gain of 12q, with the exception of a higher incidence of gains at 3q.

Entities:  

Mesh:

Year:  2006        PMID: 16321855     DOI: 10.1080/10428190500287828

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  2 in total

Review 1.  Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia.

Authors:  Russell A Higgins; Shelly R Gunn; Ryan S Robetorye
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 2.  Whole genome scanning as a cytogenetic tool in hematologic malignancies.

Authors:  Jaroslaw P Maciejewski; Ghulam J Mufti
Journal:  Blood       Date:  2008-05-27       Impact factor: 22.113

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.